CMPX vs FCX · $367.4M cap vs P/E 38, rev $13.26B
Compass Therapeutics Inc. (CMPX) versus Freeport-McMoran Copper & Gold Inc (FCX) — a side-by-side from cached financials, not a winner call.
Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on US.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Latest reported CMPX revenue for 2025-09-30 was $0. Net income was -$14.3M. CMPX currently screens at market cap $367.4M.
Latest reported FCX revenue for 2026-06-30 was $13.26B. Net income was $1.86B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
CMPX currently screens at market cap $367.4M. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Not investment advice. Open the CMPX and FCX stock pages for the full models.
Not investment advice.